Shineco, Inc. (SISI)
USD 2.12
(-4.07%)
USD 2.12
(-4.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 9.8 Million USD | 1680.61% |
| 2023 | 550.47 Thousand USD | -74.82% |
| 2022 | 2.18 Million USD | -27.64% |
| 2021 | 3.02 Million USD | -87.24% |
| 2020 | 23.68 Million USD | -24.14% |
| 2019 | 31.22 Million USD | -28.88% |
| 2018 | 43.89 Million USD | 30.68% |
| 2017 | 33.59 Million USD | -4.59% |
| 2016 | 35.2 Million USD | 7.9% |
| 2015 | 32.63 Million USD | 4.28% |
| 2014 | 31.28 Million USD | -10.04% |
| 2013 | 34.78 Million USD | 0.0% |
| 2006 | 2.1 Million USD | -33.11% |
| 2005 | 3.14 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.34 Million USD | -41.51% |
| 2024 Q1 | 1.64 Million USD | 235.18% |
| 2024 Q2 | 2.3 Million USD | 40.16% |
| 2024 Q4 | 4.49 Million USD | 233.33% |
| 2023 Q1 | 535.69 Thousand USD | 160.0% |
| 2023 Q2 | 539.24 Thousand USD | 0.66% |
| 2023 Q4 | -1.21 Million USD | -275.68% |
| 2023 Q3 | 693.03 Thousand USD | 28.52% |
| 2023 FY | 550.47 Thousand USD | -74.82% |
| 2022 Q2 | 732.57 Thousand USD | 16.33% |
| 2022 FY | 2.18 Million USD | -27.64% |
| 2022 Q1 | 629.75 Thousand USD | 110.2% |
| 2022 Q4 | 206.03 Thousand USD | -66.67% |
| 2022 Q3 | 618.09 Thousand USD | -15.63% |
| 2021 Q2 | 3.06 Million USD | -26.08% |
| 2021 Q1 | 4.14 Million USD | -17.71% |
| 2021 Q3 | 1.99 Million USD | -35.01% |
| 2021 Q4 | -6.17 Million USD | -410.21% |
| 2021 FY | 3.02 Million USD | -87.24% |
| 2020 Q1 | 7.04 Million USD | -6.62% |
| 2020 Q2 | 7.86 Million USD | 11.66% |
| 2020 Q3 | 3.73 Million USD | -52.54% |
| 2020 Q4 | 5.03 Million USD | 34.83% |
| 2020 FY | 23.68 Million USD | -24.14% |
| 2019 Q4 | 7.54 Million USD | -2.03% |
| 2019 Q3 | 7.7 Million USD | -8.1% |
| 2019 FY | 31.22 Million USD | -28.88% |
| 2019 Q1 | 7.58 Million USD | -11.9% |
| 2019 Q2 | 8.38 Million USD | 10.45% |
| 2018 Q4 | 8.61 Million USD | -35.43% |
| 2018 FY | 43.89 Million USD | 30.68% |
| 2018 Q3 | 13.34 Million USD | -5.6% |
| 2018 Q2 | 14.13 Million USD | 80.96% |
| 2018 Q1 | 7.8 Million USD | -3.12% |
| 2017 Q4 | 8.06 Million USD | 1.5% |
| 2017 Q1 | 6.36 Million USD | -21.72% |
| 2017 Q2 | 11.22 Million USD | 76.28% |
| 2017 Q3 | 7.94 Million USD | -29.24% |
| 2017 FY | 33.59 Million USD | -4.59% |
| 2016 Q3 | 7.66 Million USD | -36.8% |
| 2016 Q1 | 7.28 Million USD | -9.49% |
| 2016 Q4 | 8.13 Million USD | 6.15% |
| 2016 FY | 35.2 Million USD | 7.9% |
| 2016 Q2 | 12.12 Million USD | 66.42% |
| 2015 FY | 32.63 Million USD | 4.28% |
| 2015 Q4 | 8.04 Million USD | 15.64% |
| 2015 Q3 | 6.96 Million USD | -35.62% |
| 2015 Q2 | 10.81 Million USD | 58.79% |
| 2015 Q1 | 6.8 Million USD | -12.08% |
| 2014 Q4 | 7.74 Million USD | 11.16% |
| 2014 Q2 | 8.25 Million USD | 0.0% |
| 2014 Q3 | 6.96 Million USD | -15.58% |
| 2014 Q1 | 8.25 Million USD | -19.74% |
| 2014 FY | 31.28 Million USD | -10.04% |
| 2013 Q4 | 10.28 Million USD | 8.79% |
| 2013 FY | 34.78 Million USD | 0.0% |
| 2013 Q3 | 9.45 Million USD | 0.0% |
| 2007 Q3 | 562.56 Thousand USD | 0.0% |
| 2007 Q1 | 586.59 Thousand USD | 0.0% |
| 2006 Q3 | 444.04 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 2.1 Million USD | -33.11% |
| 2005 FY | 3.14 Million USD | 0.0% |
| 2005 Q3 | 797.38 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Theratechnologies Inc. | 81.76 Million USD | 88.012% |
| Harrow Health, Inc. | 130.19 Million USD | 92.471% |
| Dynavax Technologies Corporation | 232.28 Million USD | 95.78% |
| Biofrontera Inc. | 34.07 Million USD | 71.231% |
| Cronos Group Inc. | 88.84 Million USD | 88.967% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 23.032% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 97.786% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -50.493% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 75.218% |
| Radius Health, Inc. | 2.88 Billion USD | 99.66% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 69.662% |
| DURECT Corporation | 8.54 Million USD | -14.668% |
| ProPhase Labs, Inc. | 44.38 Million USD | 77.916% |
| Safety Shot Inc | 202.67 Thousand USD | -4736.363% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.037% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -408.264% |
| Alvotech | 91.43 Million USD | 89.28% |
| Assertio Holdings, Inc. | 152.06 Million USD | 93.554% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 98.387% |
| Rockwell Medical, Inc. | 83.61 Million USD | 88.277% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 59.316% |
| Procaps Group S.A. | 409.92 Million USD | 97.609% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 97.889% |
| SCYNEXIS, Inc. | 140.14 Million USD | 93.006% |
| Aytu BioPharma, Inc. | 81 Million USD | 87.899% |
| Viatris Inc. | 15.42 Billion USD | 99.936% |
| OptiNose, Inc. | 70.98 Million USD | 86.192% |
| SIGA Technologies, Inc. | 139.91 Million USD | 92.995% |
| Tilray Brands, Inc. | 788.94 Million USD | 98.758% |
| PetIQ, Inc. | 1.1 Billion USD | 99.111% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 59.316% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.481% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | 19.975% |
| Alimera Sciences, Inc. | 80.75 Million USD | 87.862% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 98.271% |
| Silver Spike Investment Corp. | 11.72 Million USD | 16.382% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 97.737% |
| Journey Medical Corporation | 79.18 Million USD | 87.621% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -68.348% |
| Alpha Teknova, Inc. | 36.68 Million USD | 73.28% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | 43.722% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 92.358% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 53.37 Million USD | 81.637% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 64.947% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -652.831% |
| Embecta Corp. | 1.12 Billion USD | 99.125% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | 651 Thousand USD | -1405.661% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 98.548% |
| Incannex Healthcare Limited | 12 Thousand USD | -81582.133% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -810.61% |
| Procaps Group, S.A. | 409.92 Million USD | 97.609% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 97.987% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 80.622% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.244% |
| Alvotech | 91.43 Million USD | 89.28% |
| Hempacco Co., Inc. | 4.04 Million USD | -142.282% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 96.904% |
| Bright Green Corporation | 401.49 Thousand USD | -2341.364% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 91.574% |
| Kamada Ltd. | 144.75 Million USD | 93.229% |
| Indivior PLC | 1.09 Billion USD | 99.103% |
| Evoke Pharma, Inc. | 5.18 Million USD | -89.202% |
| Flora Growth Corp. | 76.07 Million USD | 87.115% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -810.61% |
| Evolus, Inc. | 202.08 Million USD | 95.15% |
| HUTCHMED (China) Limited | 837.99 Million USD | 98.83% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 98.479% |
| Akanda Corp. | 2.16 Million USD | -353.779% |